Mariner
TLX

Mariner’s Telix Pharmaceuticals TLX Stock Holding History

Mariner’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$415K Buy
43,446
+6,864
+19% +$52.3K ﹤0.01% 2625
2025
Q4 		$274K Buy
+36,582
New +$352K ﹤0.01% 2923

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Mariner's TLX Position: Q1 2026 in Review

Mariner increased its Telix Pharmaceuticals (TLX) stake by 19% in Q1 2026, buying an estimated $52.3K and bringing the position to 43,446 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

Mariner first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Mariner held 43,446 shares of Telix Pharmaceuticals worth $415K as of Q1 2026.
  • Mariner bought 6,864 Telix Pharmaceuticals shares in Q1 2026, an estimated $52.3K.
  • Telix Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2625 holding.
  • Mariner first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.